// App-Quantinova.ai

SAT0403 : EFFICACY AND SAFETY OF 108 WEEKS’ BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • J. F. Merola

  • P. J. Mease

  • L. C. Coates

  • P. Joshi

  • J. Coarse

  • B. Ink

  • C. T. Ritchlin

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Harvard Medical School, Brigham and Women's Hospital, Boston, United States of America

  • University of Oxford, Oxford, United Kingdom

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, United States of America

  • University of Rochester Medical Center, Rochester, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Cluster of differentiation 95

  • Malondialdehyde

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT02969525

  • NCT03347110

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved